Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Kerbel, J. Folkman (2002)Clinical translation of angiogenesis inhibitors
Nature Reviews Cancer, 2
R. Guimbaud, C. Louvet, P. Ries, M. Ychou, E. Maillard, T. André, J. Gornet, T. Aparicio, S. Nguyen, A. Azzedine, P. Etienne, E. Boucher, C. Rebischung, P. Hammel, P. Rougier, L. Bedenne, O. Bouché (2014)Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 31
J Folkman, Y Shing (1992)Angiogenesis
J Biol Chem, 267
L. Shen, Jin Li, Jianming Xu, H. Pan, G. Dai, S. Qin, Li-wei Wang, Jinwan Wang, Zhenzhou Yang, Y. Shu, R. Xu, Lei Chen, Yunpeng Liu, Shiying Yu, L. Bu, Y. Piao (2014)Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
Gastric Cancer, 18
S. Koyasu (2003)The role of PI3K in immune cells
Nature Immunology, 4
E. Cutsem, S. Haas, Yoon-Koo Kang, A. Ohtsu, N. Tebbutt, Jian Xu, W. Yong, B. Langer, P. Delmar, S. Scherer, M. Shah (2012)Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 17
M. Debiec-Rychter, H. Dumez, I. Judson, B. Wasąg, J. Verweij, M. Brown, S. Dimitrijević, R. Sciot, M. Stul, H. Vranck, M. Scurr, A. Hagemeijer, M. Glabbeke, A. Oosterom (2004)Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer, 40 5
F. Innocenti, F. Ou, X. Qu, T. Zemla, D. Niedzwiecki, Rachel Tam, Shilpi Mahajan, R. Goldberg, M. Bertagnolli, C. Blanke, H. Sanoff, J. Atkins, B. Polite, A. Venook, H. Lenz, O. Kabbarah (2019)Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 14
D. Catenacci, N. Tebbutt, I. Davidenko, A. Murad, S. Al-Batran, D. Ilson, S. Tjulandin, E. Gotovkin, B. Karaszewska, I. Bondarenko, M. Tejani, A. Udrea, M. Tehfé, F. Vita, C. Turkington, R. Tang, A. Ang, Yilong Zhang, T. Hoang, R. Sidhu, D. Cunningham (2017)Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 18 11
C. Fuchs, K. Shitara, M. Bartolomeo, S. Lonardi, S. Al-Batran, E. Cutsem, D. Ilson, M. Alsina, I. Chau, J. Lacy, M. Ducreux, G. Mendez, Alejandro Alavez, D. Takahari, W. Mansoor, P. Enzinger, V. Gorbounova, Z. Wainberg, S. Hegewisch‐Becker, D. Ferry, Ji Lin, R. Carlesi, M. Das, M. Shah (2019)Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 20 3
D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, A. Norman (2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer.
The New England journal of medicine, 358 1
A. Ohtsu, M. Shah, E. Cutsem, S. Rha, A. Sawaki, Sook Park, Ho Lim, Y. Yamada, Jian Wu, B. Langer, M. Starnawski, Yoon-Koo Kang (2011)Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 30
H. Yoon, J. Bendell, F. Braiteh, I. Firdaus, P. Philip, A. Cohn, N. Lewis, D. Anderson, E. Arrowsmith, J. Schwartz, L. Gao, Y. Hsu, Y. Xu, D. Ferry, S. Alberts, Z. Wainberg (2019)Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 30 12
S. Al-Batran, J. Hartmann, S. Probst, H. Schmalenberg, S. Hollerbach, R. Hofheinz, V. Rethwisch, G. Seipelt, N. Homann, G. Wilhelm, G. Schuch, J. Stoehlmacher, H. Derigs, S. Hegewisch‐Becker, J. Grossmann, C. Pauligk, A. Atmaca, C. Bokemeyer, A. Knuth, E. Jäger (2008)Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 9
F. Lordick, Yoon-Koo Kang, H. Chung, P. Salman, S. Oh, G. Bodoky, G. Kurteva, C. Volovăț, V. Moiseyenko, V. Gorbunova, Joon-Oh Park, A. Sawaki, I. Celik, Heiko Götte, H. Melezínková, M. Moehler (2013)Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
The Lancet. Oncology, 14 6
C. Fuchs, J. Tomasek, Cho Yong, Filip Dumitru, R. Passalacqua, C. Goswami, H. Safran, L. Santos, G. Aprile, D. Ferry, B. Melichar, M. Tehfé, E. Topuzov, J. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A. Liepa, L. Gao, J. Schwartz, J. Tabernero (2014)Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
The Lancet, 383
Shelley Zhang, D. Gozal, L. Sachleben, M. Rane, J. Klein, E. Gozal (2003)Hypoxia induces an autocrine‐paracrine survival pathway via platelet‐derived growth factor (PDGF)‐B/PDGF‐β receptor/phosphatidylinositol 3‐kinase/Akt signaling in RN46A neuronal cells
The FASEB Journal, 17
M. Ohta, H. Konno, Tatsuo Tanaka, Megumi Baba, K. Kamiya, T. Syouji, K. Kondoh, Masaya Watanabe, Hirofumi Terada, Satoshi Nakamura (2003)The significance of circulating vascular endothelial growth factor (VEGF) protein in gastric cancer.
Cancer letters, 192 2
G. Yancopoulos, S. Davis, N. Gale, J. Rudge, S. Wiegand, J. Holash (2000)Vascular-specific growth factors and blood vessel formation
Y. Bang, E. Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, Julie Hill, M. Lehle, J. Rüschoff, Yoon-Koo Kang (2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet, 376
R Guimbaud, C Louvet, P Ries, M Ychou, E Maillard, T André (2014)Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (F�d�ration Francophone de Canc�rologie Digestive
Féd J Clin Oncol., 32
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA: A Cancer Journal for Clinicians, 68
M. Shah, Y. Bang, F. Lordick, M. Alsina, Meng Chen, S. Hack, J. Bruey, Dustin Smith, I. McCaffery, D. Shames, S. Phan, D. Cunningham (2017)Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial
JAMA Oncology, 3
M. Moehler, Irina Gepfner-Tuma, A. Maderer, P. Thuss-Patience, J. Ruessel, S. Hegewisch‐Becker, H. Wilke, S. Al-Batran, M. Rafiyan, F. Weissinger, H. Schmoll, F. Kullmann, L. Weikersthal, J. Siveke, Jens Weusmann, S. Kanzler, C. Schimanski, M. Otte, L. Schollenberger, J. Koenig, P. Galle (2016)Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
BMC Cancer, 16
H. Wilke, K. Muro, E. Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, Tae-You Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J. Schwartz, A. Ohtsu (2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
The Lancet. Oncology, 15 11
T. Waddell, I. Chau, D. Cunningham, David Gonzalez, A. Okines, A. Wotherspoon, C. Saffery, G. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T. Crosby, F. Coxon, David Smith, J. Waters, T. Iveson, S. Falk, S. Slater, C. Peckitt, Y. Barbáchano (2013)Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
The Lancet Oncology, 14
Guadalupe Aparicio-Gallego, Moisés Blanco, Angélica Figueroa, R. García-Campelo, M. Valladares-Ayerbes, E. Grande-Pulido, L. Antón-Aparicio (2011)New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Molecular Cancer Therapeutics, 10
BackgroundSunitinib (S) is a multi-targeted tyrosine kinase inhibitor. It is synergistic with chemotherapy in preclinical models. We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.ObjectiveSince the outcomes of advanced gastric and GEJ adenocarcinoma patients are poor, we decided to study a combination of FOLFIRI + S, to establish tolerability and efficacy.Patients and methodsThis was a phase I study for patients with advanced chemo-naïve gastric or GEJ adenocarcinoma. Dose escalation used a standard 3 + 3 design. The primary objective was to determine the tolerability and safety of FOLFIRI + S. Secondary objectives were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).ResultsA total of 23 patients participated in the study (male 78%, female 22%). The median age was 61 (range: 38–77) years. Median follow-up time was 67.5 (95% CI 58.9–76) months. The most frequently reported adverse events were anemia (78%; G3/4: 4%), neutropenia (78%; G3/4: 43%), nausea (74%; G3/4:13%), diarrhea (65%; G3/4: 4%), vomiting (61%, G3/4: 9%) lymphopenia (52%; G3/4: 13%), and fatigue (52%; G3/4:17%). Two dose-limiting toxicities were noted each at dose level (DL) 1 and 1A, one at DL 1B, and three at DL 2. Maximum tolerated dose was determined at DL 1B. At the time of data reporting, 21 patients had died. The median OS and PFS were 12.4 (95% CI 8.9, 16.5) months and 6.2 (95% CI 3.4, 13.5) months, respectively. Of all patients, 35% (eight out of 23) had a partial response.ConclusionsFOLFIRI + S has signs of clinical activity in patients with advanced gastric and GEJ adenocarcinoma, and the side-effect profile was similar to previously reported studies. Current treatment paradigms in gastric cancer probably negate further study of this regimen.ClinicalTrials.gov identifier: NCT00524186.
Targeted Oncology – Springer Journals
Published: Feb 4, 2020
Access the full text.
Sign up today, get DeepDyve free for 14 days.